Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.
According to Novo Nordisk's latest financial reports the company's current EPS (TTM) is A$6.15. In 2025 the company made an earnings per share (EPS) of A$5.08 an increase over its 2024 EPS that were of A$4.69.